Univest
Univest
  • Markets

Amanta Healthcare Analyst Review 2027: Profit Up Fourfold as the Stock Nears Its High

  • November 19, 2026
  • Posted by: Ankit Jaiswal
  • Category: Market
No Comments
Amanta Healthcare Analyst Review 2027: Profit Up Fourfold as the Stock Nears Its High

Amanta Healthcare Stock Snapshot (19 Nov 2026)

  • Current Market Price (CMP): ₹239.15
  • 52-Week High / Low: ₹245.70 / ₹92.00
  • Market Capitalisation: ₹928 crore
  • P/E Ratio vs Industry P/E: 50.7 vs 51.5
  • Latest Quarter (Q2 FY27) Revenue: ₹83.13 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹4.86 crore

Quick Answer: The Amanta Healthcare analyst review 2027 finds no named brokerage coverage as of November 2026. Q2 FY27 revenue rose 17.3% to ₹83.13 crore, EBITDA was ₹17.95 crore with a 21.6% margin, and net profit rose to ₹4.86 crore from ₹1.21 crore. The stock traded at ₹239.15 on 19 November 2026, close to its 52-week high and about 51 times earnings, so the Amanta Healthcare share price target 2027 question depends on whether profit growth can keep pace with the rally.

The Amanta Healthcare analyst review 2027 covers a Gujarat-based maker of sterile liquid medicines, including IV fluids, small-volume injectables and eye and respiratory solutions packed in plastic containers. Readers searching for an Amanta Healthcare share price target 2027 will not find any named brokerage figure, so results and valuation guide this review.

Amanta Healthcare traded at ₹239.15 on 19 November 2026, about 3% below its 52-week high of ₹245.70 and roughly 2.6 times its low of ₹92. This Amanta Healthcare analyst review 2027 explains the drivers behind the rally and the Amanta Healthcare stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Amanta Healthcare Analyst Review 2027
  • Q2 FY27 Results in the Amanta Healthcare Analyst Review 2027
  • How Amanta Healthcare Makes Money
  • Growth Triggers in the Amanta Healthcare Analyst Review 2027
  • Key Risks in the Amanta Healthcare Analyst Review 2027
  • Amanta Healthcare Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Amanta Healthcare Analyst Review 2027
  • Final Word on the Amanta Healthcare Analyst Review 2027
  • Frequently Asked Questions
    • What does the Amanta Healthcare analyst review 2027 show?
    • Is there an Amanta Healthcare share price target 2027 from brokerages?
    • What does Amanta Healthcare make?
    • How will the solar plant help Amanta Healthcare?
    • Is Amanta Healthcare stock expensive based on the Amanta Healthcare analyst review 2027?
    • What risks does the Amanta Healthcare analyst review 2027 highlight?
    • What should investors track after the Amanta Healthcare analyst review 2027?

What Analysts Say in the Amanta Healthcare Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

No named brokerage report with a target price could be verified. Amanta listed on the exchanges in 2025, and small recently listed pharma companies often go without regular research coverage.

Domestic institutions nonetheless hold about 12.2% of the company, and that stake rose over the past year. This Amanta Healthcare analyst review 2027 uses that institutional interest and the quarterly numbers as the main reference points.

Q2 FY27 Results in the Amanta Healthcare Analyst Review 2027

Metric Q2 FY27 Q2 FY26 Change
Revenue ₹83.13 crore ₹70.89 crore Up 17.3%
EBITDA ₹17.95 crore Not compared Margin 21.6%
Net profit ₹4.86 crore ₹1.21 crore Up about 302%
H1 FY27 revenue ₹151.94 crore Not compared Growing
H1 FY27 net profit ₹8.17 crore ₹4.71 crore Up about 73%

Revenue grew steadily and EBITDA margin was a healthy 21.6%. The sharp jump in quarterly profit partly reflects an exceptional item of about ₹3 crore that affects the year-on-year comparison, so the first-half figure is a cleaner guide.

First-half net profit rose about 73% to ₹8.17 crore, with the June quarter at ₹3.31 crore and the September quarter at ₹4.86 crore. In this Amanta Healthcare analyst review 2027, that sequential rise is the more useful signal.

How Amanta Healthcare Makes Money

Amanta makes sterile liquid medicines using blow-fill-seal technology, which forms, fills and seals plastic containers in one step to keep products sterile.

  • Large-volume IV fluids: saline, dextrose and other infusion solutions for hospitals.
  • Small-volume injectables: ampoules and vials for injectable drugs.
  • Eye and respiratory products: drops and nebuliser solutions in single-dose packs.
  • Exports and contract work: supplies to overseas markets and other pharma companies.

Sterile liquids are a volume business where plant utilisation and power costs decide margins. Amanta has commissioned a 10.8 MW solar power plant that it expects to save about ₹9 crore a year in electricity costs, a meaningful amount against quarterly EBITDA of about ₹18 crore. That saving frames this Amanta Healthcare analyst review 2027, because lower power costs flow almost directly into profit.

Demand for IV fluids is steady, since hospitals need them regardless of economic cycles, but pricing is competitive and some products fall under government price controls. Exports and newer specialty products such as respiratory solutions offer better margins. Pharma stocks tracked by the Nifty Pharma index have mostly larger, branded businesses, while Amanta sits in the more commoditised but steady hospital supplies segment.

Debt to equity of about 0.89 is relatively high, which means interest costs take a meaningful share of operating profit. That is one reason net profit of ₹4.86 crore is much smaller than EBITDA of ₹17.95 crore, along with depreciation on the plant. Reducing debt from cash flow would widen the gap between EBITDA and profit in shareholders’ favour.

Growth Triggers in the Amanta Healthcare Analyst Review 2027

  • Revenue growth: up 17.3% in Q2 FY27.
  • Solar savings: about ₹9 crore a year from the 10.8 MW plant.
  • Healthy margins: EBITDA margin of 21.6%.
  • Institutional interest: DII holding up to 12.2%.
  • Specialty products: eye and respiratory lines support the Amanta Healthcare share price target 2027 case.

Key Risks in the Amanta Healthcare Analyst Review 2027

  • Valuation: about 51 times trailing earnings after a sharp rally.
  • Debt: debt to equity of about 0.89.
  • Price controls: some IV fluids face government pricing caps.
  • Regulatory checks: sterile plants face strict quality inspections.
  • Small profit base: quarterly profit under ₹5 crore, a key point in the Amanta Healthcare analyst review 2027.

Compare Amanta Healthcare With Other Pharma Stocks on the Univest Screener

Amanta Healthcare Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (19 Nov 2026) ₹239.15
52-Week High / Low ₹245.70 / ₹92.00
Market Capitalisation About ₹928 crore
P/E (TTM) About 50.7
Industry P/E About 51.5
Price to Book About 4.1
Return on Equity About 8.0%
Debt to Equity 0.89
Book Value per Share ₹58.75

The P/E of about 51 is in line with the industry level, but return on equity is only about 8%. In this Amanta Healthcare analyst review 2027, the stock is priced for strong future growth, which leaves little room for a weak quarter.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 63.56% 63.80% Up 0.24 points
Foreign Investors (FII) 1.00% 0.07% Down 0.93 points
Domestic Institutions (DII) 11.34% 12.20% Up 0.86 points
Public 24.10% 23.93% Down 0.17 points

Bhavesh Patel holds 16.31% and Vishal Patel 10.06%, and the promoter stake edged higher. Domestic institutions added while foreign investors almost exited, a mixed signal in the Amanta Healthcare analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Amanta Healthcare Analyst Review 2027

  • Margins: EBITDA margin holding above 20%.
  • Solar benefit: lower power costs in coming quarters.
  • Debt: repayment and interest costs.
  • Product mix: growth in specialty and export lines.
  • Coverage: any named note on the Amanta Healthcare share price target 2027.

Final Word on the Amanta Healthcare Analyst Review 2027

The Amanta Healthcare analyst review 2027 shows steady revenue growth, healthy margins and cost savings from solar power, set against high debt, a small profit base and a valuation that already prices in growth after a sharp rally.

The Amanta Healthcare stock outlook 2027 depends on margins, debt reduction and product mix. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Amanta Healthcare analyst review 2027 show?

It shows steady growth with healthy margins. Q2 FY27 revenue rose 17.3% to ₹83.13 crore and EBITDA was ₹17.95 crore with a 21.6% margin. Net profit rose to ₹4.86 crore from ₹1.21 crore.

Is there an Amanta Healthcare share price target 2027 from brokerages?

No named brokerage target could be verified as of November 2026. The stock traded at ₹239.15 on 19 November 2026, about 3% below its 52-week high of ₹245.70. Results are the main reference point.

What does Amanta Healthcare make?

Amanta makes sterile liquid medicines such as IV fluids, small-volume injectables and eye and respiratory solutions. It uses blow-fill-seal technology to fill plastic containers. It sells to hospitals, export markets and other pharma companies.

How will the solar plant help Amanta Healthcare?

Amanta has a 10.8 MW solar power plant that it expects to save about ₹9 crore a year in power costs. That is large against quarterly EBITDA of about ₹18 crore. The savings flow almost directly into profit.

Is Amanta Healthcare stock expensive based on the Amanta Healthcare analyst review 2027?

The stock trades at about 51 times earnings, in line with the industry P/E of about 51.5. Return on equity is only about 8% and price to book is about 4.1. The price assumes strong future growth.

What risks does the Amanta Healthcare analyst review 2027 highlight?

The main risks are a high valuation after a sharp rally and debt to equity of about 0.89. Some IV fluids face government price controls. Sterile plants also face strict quality inspections.

What should investors track after the Amanta Healthcare analyst review 2027?

Track whether EBITDA margin stays above 20% and how much the solar plant cuts power costs. Watch debt reduction and interest costs. Growth in specialty and export products also matters.



2027 Amanta Healthcare Analyst Review Sterile Injectables and IV Fluids
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply